What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence
© The Author(s) 2023. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd..
BACKGROUND: More than 90% of patients developing heart failure (HF) have an epidemiological background of hypertension. The most frequent concomitant conditions are type 2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease, all disorders/diseases closely related to hypertension.
METHODS: HF outcome research focuses on decreasing mortality and preventing hospitalization for worsening HF syndrome. All drugs that decrease these HF endpoints lower blood pressure. Current drug treatments for HF are (i) angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor neprilysin inhibitors, (ii) selected beta-blockers, (iii) steroidal and nonsteroidal mineralocorticoid receptor antagonists, and (iv) sodium-glucose cotransporter 2 inhibitors.
RESULTS: For various reasons, these drug treatments were first studied in HF patients with a reduced ejection fraction (HFrEF). However, subsequently, they have been investigated and, as we see it, documented as beneficial in HF patients with a preserved left ventricular ejection fraction (LVEF, HFpEF) and mostly hypertensive etiology, with effect estimates assessed partly on top of background treatment with the drugs already proven effective in HFrEF. Additionally, diuretics are given on symptomatic indications.
CONCLUSIONS: Considering the totality of evidence and the overall need for antihypertensive treatment and/or treatment of hypertensive complications in almost all HF patients, the principal drug treatment of HF appears to be the same regardless of LVEF. Rather than LVEF-guided treatment of HF, treatment of HF should be directed by symptoms (related to the level of fluid retention), signs (tachycardia), severity (NYHA functional class), and concomitant diseases and conditions. All HF patients should be given all the drug classes mentioned above if well tolerated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
American journal of hypertension - 37(2023), 1 vom: 01. Jan., Seite 1-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sevre, Kaja [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 18.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ajh/hpad073 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360515797 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360515797 | ||
| 003 | DE-627 | ||
| 005 | 20231227133645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajh/hpad073 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1231.xml |
| 035 | |a (DE-627)NLM360515797 | ||
| 035 | |a (NLM)37551929 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sevre, Kaja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 18.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. | ||
| 520 | |a BACKGROUND: More than 90% of patients developing heart failure (HF) have an epidemiological background of hypertension. The most frequent concomitant conditions are type 2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease, all disorders/diseases closely related to hypertension | ||
| 520 | |a METHODS: HF outcome research focuses on decreasing mortality and preventing hospitalization for worsening HF syndrome. All drugs that decrease these HF endpoints lower blood pressure. Current drug treatments for HF are (i) angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor neprilysin inhibitors, (ii) selected beta-blockers, (iii) steroidal and nonsteroidal mineralocorticoid receptor antagonists, and (iv) sodium-glucose cotransporter 2 inhibitors | ||
| 520 | |a RESULTS: For various reasons, these drug treatments were first studied in HF patients with a reduced ejection fraction (HFrEF). However, subsequently, they have been investigated and, as we see it, documented as beneficial in HF patients with a preserved left ventricular ejection fraction (LVEF, HFpEF) and mostly hypertensive etiology, with effect estimates assessed partly on top of background treatment with the drugs already proven effective in HFrEF. Additionally, diuretics are given on symptomatic indications | ||
| 520 | |a CONCLUSIONS: Considering the totality of evidence and the overall need for antihypertensive treatment and/or treatment of hypertensive complications in almost all HF patients, the principal drug treatment of HF appears to be the same regardless of LVEF. Rather than LVEF-guided treatment of HF, treatment of HF should be directed by symptoms (related to the level of fluid retention), signs (tachycardia), severity (NYHA functional class), and concomitant diseases and conditions. All HF patients should be given all the drug classes mentioned above if well tolerated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a angiotensin receptor blocker | |
| 650 | 4 | |a angiotensin receptor neprilysin inhibitor | |
| 650 | 4 | |a angiotensin-converting enzyme inhibitor | |
| 650 | 4 | |a beta-blocker | |
| 650 | 4 | |a blood pressure | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a mineralocorticoid receptor antagonist | |
| 650 | 4 | |a sodium-glucose cotransporter 2 inhibitor | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 700 | 1 | |a Rist, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Wachtell, Kristian |e verfasserin |4 aut | |
| 700 | 1 | |a Devereux, Richard B |e verfasserin |4 aut | |
| 700 | 1 | |a Aurigemma, Gerard P |e verfasserin |4 aut | |
| 700 | 1 | |a Smiseth, Otto A |e verfasserin |4 aut | |
| 700 | 1 | |a Kjeldsen, Sverre E |e verfasserin |4 aut | |
| 700 | 1 | |a Julius, Stevo |e verfasserin |4 aut | |
| 700 | 1 | |a Pitt, Bertram |e verfasserin |4 aut | |
| 700 | 1 | |a Burnier, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Kreutz, Reinhold |e verfasserin |4 aut | |
| 700 | 1 | |a Oparil, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Mancia, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hypertension |d 1988 |g 37(2023), 1 vom: 01. Jan., Seite 1-14 |w (DE-627)NLM012611670 |x 1941-7225 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:1-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajh/hpad073 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 1 |b 01 |c 01 |h 1-14 | ||